- Home
- QNCX vs ICCC Comparison
QNCX vs ICCC Comparison
Compare QNCX & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNCX
- ICCC
- Stock Information
- Founded
- QNCX 2012
- ICCC 1982
- Country
- QNCX United States
- ICCC United States
- Employees
- QNCX N/A
- ICCC N/A
- Industry
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- ICCC Biotechnology: Pharmaceutical Preparations
- Sector
- QNCX Health Care
- ICCC Health Care
- Exchange
- QNCX Nasdaq
- ICCC Nasdaq
- Market Cap
- QNCX 34.4M
- ICCC 28.0M
- IPO Year
- QNCX 2019
- ICCC 1987
- Fundamental
- Price
- QNCX $2.08
- ICCC $3.66
- Analyst Decision
- QNCX Strong Buy
- ICCC
- Analyst Count
- QNCX 3
- ICCC 0
- Target Price
- QNCX $9.67
- ICCC N/A
- AVG Volume (30 Days)
- QNCX 1.1M
- ICCC 14.5K
- Earning Date
- QNCX 11-13-2024
- ICCC 11-13-2024
- Dividend Yield
- QNCX N/A
- ICCC N/A
- EPS Growth
- QNCX N/A
- ICCC N/A
- EPS
- QNCX N/A
- ICCC N/A
- Revenue
- QNCX N/A
- ICCC $23,838,002.00
- Revenue This Year
- QNCX N/A
- ICCC N/A
- Revenue Next Year
- QNCX N/A
- ICCC N/A
- P/E Ratio
- QNCX N/A
- ICCC N/A
- Revenue Growth
- QNCX N/A
- ICCC 46.37
- 52 Week Low
- QNCX $0.51
- ICCC $3.34
- 52 Week High
- QNCX $2.14
- ICCC $5.59
- Technical
- Relative Strength Index (RSI)
- QNCX 73.91
- ICCC 54.28
- Support Level
- QNCX $1.56
- ICCC $3.40
- Resistance Level
- QNCX $2.14
- ICCC $3.64
- Average True Range (ATR)
- QNCX 0.21
- ICCC 0.16
- MACD
- QNCX 0.02
- ICCC 0.01
- Stochastic Oscillator
- QNCX 91.89
- ICCC 65.12
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.